Logo
x

Search category

Subscribe Now

Pain

Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain

Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain

  • March 17, 2023
Myovant and Pfizer’s Myfembree Receive the US FDA’s Approval for the Treatment of Pain Associated with Endometriosis

Myovant and Pfizer’s Myfembree Receive the US FDA’s Approval for the Treatment of Pain Associated with Endometriosis

  • August 8, 2022
Zomedica Acquires Assisi’s Assets and Provide Drug-Free Solution for Treating Pain

Zomedica Acquires Assisi’s Assets and Provide Drug-Free Solution for Treating Pain

  • July 18, 2022
Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Followi...

  • June 29, 2022
Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery

Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery

  • May 13, 2022
The US FDA Extends Review Period of Myfembree’s sNDA to Treat Moderate to Severe Pain Associated with Endometriosis

The US FDA Extends Review Period of Myfembree’s sNDA to Treat Moderate to Severe Pain Associated with Endometriosis

  • May 9, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.